KRCC1 activators encompass a novel chemical class designed to enhance the activity of KRCC1, a protein that may play a crucial role in cellular processes such as DNA repair, cell cycle regulation, and the response to cellular stress. The development of activators for this protein is predicated on the understanding that enhancing KRCC1 activity could have beneficial effects in contexts where increased DNA repair capacity, improved cellular resilience to stress, or more tightly regulated cell cycle progression is desirable. The initial phase of discovering KRCC1 activators often involves the use of high-throughput screening (HTS) techniques to identify compounds capable of interacting with KRCC1 in a manner that enhances its activity. This screening process aims to uncover molecules that can bind directly to KRCC1 or its cofactors and modulate the protein's conformation, stability, or interaction with other cellular components in a way that upregulates its functional activity.
Following the identification of potential activators through HTS, structure-activity relationship (SAR) studies are integral to refining these compounds to improve their efficacy, specificity, and pharmacokinetic properties. SAR studies involve meticulously modifying the chemical structure of identified leads to elucidate how these changes impact their ability to activate KRCC1. Through this iterative process, compounds are optimized to ensure they are potent and selective activators of KRCC1, with minimal off-target effects and suitable characteristics for in vivo use. Techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy play a critical role in this optimization phase, providing detailed insights into the molecular interactions between KRCC1 and the activators. This structural information is invaluable for guiding the rational design of more effective activators. Additionally, cellular assays are employed to assess the impact of these activators within a biological context, confirming their ability to enhance KRCC1 activity in living cells and to elucidate the resulting effects on cellular processes regulated by KRCC1. Through a comprehensive approach that combines targeted chemical synthesis, structural analysis, and functional validation, KRCC1 activators are developed with the aim of modulating the protein's activity precisely.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K 8644 is a calcium channel agonist. It activates KRCC1 by enhancing calcium influx through the channel. Increased intracellular calcium levels then promote potassium channel activation. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid is an NSAID that can activate KRCC1. It may do so by altering the ion conductance properties of the channel, leading to enhanced potassium ion efflux. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Isradipine indirectly activates KRCC1 by reducing calcium levels. As a calcium channel blocker, it decreases intracellular calcium, which can lead to potassium channel activation through downstream signaling pathways. | ||||||
Pinacidil monohydrate | 85371-64-8 | sc-203198 sc-203198A | 10 mg 50 mg | $51.00 $95.00 | 6 | |
Pinacidil is a vasodilator drug that activates KRCC1 by promoting potassium channel opening. This leads to membrane hyperpolarization and increased potassium ion efflux. | ||||||
DCEBIO | 60563-36-2 | sc-203561 sc-203561A | 10 mg 50 mg | $107.00 $417.00 | 3 | |
DCEBIO is a chemical compound that activates KRCC1 by enhancing potassium ion conductance through the channel. It facilitates the opening of potassium channels, leading to increased potassium ion efflux. | ||||||